Fluorescence imaging IDs residual tumor in lumpectomy cavity fast

June 27, 2018
New clinical data shows rapid, direct identification of residual tumor in breast cancer patients during surgery with fluorescence imaging.

Lumicell (Wellesley, MA) has published further clinical data demonstrating rapid and direct identification of residual tumor in the lumpectomy cavities of breast cancer patients during surgery with its LUM System, a fluorescence imaging for tumor detection.

The results, which were published by investigators at Massachusetts General Hospital (MGH; Boston, MA) in the July 2018 issue of Breast Cancer Research and Treatment, further support Phase 2 data presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2017 showing complete and instantaneous detection of residual cancer in the tumor cavity and the ability to detect all breast cancer subtypes with the integrated LUM system. The system integrates the immuno- and cancer-targeted optical agent LUM015, the company's handheld imaging device, and decision software to detect cancer cells in real time during surgery.

Related: Fluorescence system correctly identifies residual cancer cells across breast cancer subtypes

In the paper describing the work, Barbara Smith, MD, Ph.D., director of the Breast Program at MGH and Professor of Surgery at Harvard Medical School, and colleagues from MGH demonstrate that the LUM System provided high sensitivity for tumor detection, rapid assessment of the entire lumpectomy cavity, and precise identification of sites of tumor in the lumpectomy cavity wall with no adverse effects. In addition, no significant background autofluorescence was detected in benign human breast tissue, supporting the use of a fluorescence-based strategy for lumpectomy margin assessment.

"With current histopathology-based margin assessment technology, 20-40% of breast cancer lumpectomy patients have positive surgical margins that require a second surgery to achieve clear margins," says Kelly Londy, Lumicell's CEO. "In contrast, the LUM System can directly identifying sites of residual tumor for excision and can be used repeatedly during that first surgery until no residual tumor signal remains."

For more information, please visit www.lumicell.com.

About the Author

BioOptics World Editors

We edited the content of this article, which was contributed by outside sources, to fit our style and substance requirements. (Editor’s Note: BioOptics World has folded as a brand and is now part of Laser Focus World, effective in 2022.)

Sponsored Recommendations

Melles Griot® XPLAN™ CCG Lens Series

March 19, 2024
IDEX Health & Science sets a new standard with our Melles Griot® XPLAN™ CCG Lens Series fluorescence microscope imaging systems. Access superior-quality optics with off-the-shelf...

Spatial Biology

March 19, 2024
Spatial Biology refers to the field that integrates spatial information into biological research, allowing for the study of biological systems in their native spatial context....

Fluorescent Protein Optical Imaging Considerations

March 19, 2024
What factors should you consider when your incorporate fluorescent proteins in an optical imaging application? Learn more.

Custom-Engineered Optical Solutions for Your Application

March 19, 2024
We combine advanced optical design and manufacturing technology, with decades of experience in critical applications, to take you from first designs to ongoing marketplace success...

Voice your opinion!

To join the conversation, and become an exclusive member of Laser Focus World, create an account today!